Cohance Lifesciences Limited vs Granules India Limited
Last updated: 5 November 2026
MoneyDock presents a comparative analysis between Cohance Lifesciences Limited (COHANCE.NS) and Granules India Limited (GRANULES.NS), two prominent players in the Indian pharmaceutical sector. While both companies contribute significantly to the healthcare landscape, they cater to different segments and scales within the industry. This comparison aims to provide investors with a clear, data-driven perspective on their current market positions, financial performance, and potential suitability for various investment strategies, based purely on the provided metrics.
Key Financial Metrics Comparison
| Metric | Cohance Lifesciences Limited | Granules India Limited |
|---|---|---|
| Current Price | ₹449.00 | ₹794.45 |
| 52-Week High | ₹537.35 | ₹909.30 |
| 52-Week Low | ₹279.90 | ₹537.55 |
| 1-Year Return | -16.44% | 28.69% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
Valuation: With both companies showing 'N/A' for Trailing P/E and Market Cap, a direct valuation comparison based on these common metrics is not possible from the given data. Investors would need to look into other financial statements to assess their fundamental valuation. However, Granules India has a significantly higher current price at ₹794.45 compared to Cohance Lifesciences at ₹449.00, suggesting it might be perceived as a larger or more established entity, although this cannot be confirmed without market capitalization figures.
Returns: Granules India Limited clearly outperforms Cohance Lifesciences Limited in terms of 1-Year Return. Granules India boasts a positive return of 28.69%, indicating strong recent growth and investor confidence. In stark contrast, Cohance Lifesciences has experienced a negative return of -16.44% over the same period, suggesting a period of underperformance or correction. For investors prioritizing recent capital appreciation, Granules India presents a more favorable picture.
Stability: Stability can be inferred by examining the 52-week price range relative to the current price. Cohance Lifesciences' current price of ₹449.00 is well above its 52-week low of ₹279.90 but significantly below its 52-week high of ₹537.35, implying it has experienced a notable drawdown from its peak. Granules India, with a current price of ₹794.45, is also above its 52-week low of ₹537.55 but closer to its 52-week high of ₹909.30 compared to Cohance, suggesting a relatively steadier performance closer to its peak or a less severe decline from it. Granules' positive 1-year return also contributes to an impression of greater recent stability and growth trajectory.
MoneyDock Verdict
For Aggressive Investors: Granules India Limited appears to be the more attractive option given its robust 1-year return of 28.69%. Aggressive investors seeking higher growth potential might find its recent performance more compelling, despite the lack of P/E or Market Cap for deeper valuation analysis.
For Conservative Investors: With the available data, neither company presents a strong case for conservative investors primarily due to the absence of crucial valuation metrics like Trailing P/E and Market Cap. Cohance Lifesciences' negative 1-year return makes it less appealing. Conservative investors would typically seek more complete financial information to gauge risk and stability before making an investment decision.
For Long-Term SIP Investors: Granules India's positive and strong 1-year return suggests a potentially more consistent growth story, which could be beneficial for long-term Systematic Investment Plans (SIPs). However, the lack of comprehensive valuation metrics means investors should proceed with caution and conduct further research into the companies' fundamentals and future prospects beyond the provided figures to ensure alignment with long-term goals.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.